title: Future treatment for asthma.
abstract: The landscape of asthma has considerably changed after 40 years of inhaled corticosteroid development and nearly 20 years since the first monoclonal antibodies (mAbs) were approved. New members of pharmacological families and more effective drug-delivery devices have been designed but the proportion of uncontrolled patients, unfortunately, remains stable. The most promising treatments now rely on targeted therapies that encourage the improvement of the characterisation of our patients. These clinical (phenotype) or new biological (endotype) tools lead to palpable personalised medicine. This review examines not only the future of mAbs and other new ways of treating asthma but also describes futuristic views based on the paradigm shifts that are ready to occur.
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Charriot
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Vachier
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Halimi
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Gamez
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Clement
authors.initials: C
authors.lastname: Boissin
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Marine
authors.initials: M
authors.lastname: Salama
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Alina
authors.initials: A
authors.lastname: Cucu-Jarjour
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France.
authors.forename: Engi
authors.initials: E
authors.lastname: Ahmed
authors.affiliation: Dept of Respiratory Diseases, CHU Montpellier, Montpellier, France PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Hôpital Arnaud de Villeneuve, Montpellier, France a-bourdin@chu-montpellier.fr.
authors.forename: Arnaud
authors.initials: A
authors.lastname: Bourdin
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D015415:Biomarkers / Q000378:metabolism; D055808:Drug Discovery / Q000639:trends*; D005544:Forecasting; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D058990:Molecular Targeted Therapy / Q000639:trends*; D010641:Phenotype; D057285:Precision Medicine / Q000639:trends*
chemical_list: D018927:Anti-Asthmatic Agents; D015415:Biomarkers